Spruce Biosciences

Historical price data

Spruce Biosciences is a public, clinical-stage biotech focused on rare neurological and endocrine disorders, with its lead asset, TA-ERT, in Phase 3 for MPS IIIB. The company operates with a patient-inspired development model, leveraging a seasoned leadership team with deep expertise in rare disease drug development and commercialization. Its strategy centers on advancing targeted therapies through late-stage clinical trials, supported by a strong financial position from prior capital raises, while navigating the high-risk, high-reward landscape of orphan drug development. Spruce has cultivated an award-winning corporate culture recognized for employee engagement and innovation.

Spruce is a product-focused company with a development philosophy centered on patient-inspired science, applying established therapeutic modalities like enzyme replacement therapy (ERT) to rare disorders with high unmet need.

In MPS IIIB, Spruce faces competition from gene therapy and other ERT developers, though TA-ERT is among the most advanced ERT candidates. The lack of any approved disease-modifying therapy presents a first-mover opportunity but also intense pressure to demonstrate clear efficacy.